Orphina Biotechnology

Orphina Biotechnology is a private, pre-revenue company founded in 2021 with a mission to cure GNE Myopathy and other muscle-wasting illnesses. The company's lead program, H001, is a non-viral gene therapy for GNEM designed for re-dosability and targeted delivery to limb muscles, currently in the pre-clinical/IND-enabling stage. Orphina's strategy leverages deep community engagement with patients and clinicians to advance a pipeline that addresses significant unmet needs in rare neuromuscular diseases. The company is led by its founder, Dr. Daniel Darvish, who is both a physician and a patient, driving a patient-centric R&D approach.

Non-viral and viral gene therapy platform designed for targeted delivery to skeletal muscles, with a key feature of enabling re-dosing while limiting exposure to vital internal organs to improve safety and efficacy.

Direct competition in GNEM is limited, but the broader field of gene therapy for muscle diseases is dominated by AAV vectors from larger biotechs. Orphina's key differentiation is its focus on re-dosability and organ-specific targeting to improve safety, a significant hurdle for current AAV approaches. Success depends on proving its platform's advantages over these established modalities.